Royalty Pharma (RPRX) Minority Interest (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Minority Interest data on file, last reported at $3.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Minority Interest fell 1.67% year-over-year to $3.0 billion; the trailing twelve-month figure through Mar 2026 stood at $3.0 billion (down 1.67% YoY), and the FY2025 full-year result was $3.2 billion, down 4.65% from the prior year.
• Minority Interest retreated to $3.0 billion in Q1 2026, from $3.2 billion in the prior quarter.
• In the past five years, Minority Interest ranged from a high of $4.4 billion in Q2 2022 to a low of $3.0 billion in Q1 2026.
• A 5-year average of $3.6 billion and a median of $3.4 billion in 2024 frame the typical range for Minority Interest.
• Across the five-year window, Minority Interest retreated 19.38% in 2023 and retreated 1.67% in 2026, its largest moves.
• Tracing RPRX's Minority Interest over 5 years: stood at $3.9 billion in 2022, then slipped by 8.71% to $3.6 billion in 2023, then fell by 4.55% to $3.4 billion in 2024, then decreased by 4.65% to $3.2 billion in 2025, then retreated by 5.86% to $3.0 billion in 2026.
• Business Quant data shows RPRX's Minority Interest at $3.0 billion in Q1 2026, $3.2 billion in Q4 2025, and $3.2 billion in Q3 2025.